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Abstract
Inactivating mutations in the p53 tumor suppressor gene occur often in the progression of human cancers. p53 inhibits the
outgrowth of nascent cancer cells through anti-proliferative actions (including induction of apoptosis or senescence). To
test p53 tumor suppressor functions in a novel experimental context, we somatically deleted both p53 alleles in multiple
tissues of mice at various ages. Mice homozygously deleted for p53 at 3 months of age showed a longer tumor latency
compared to mice deleted for p53 at 6 and 12 months of age. These results are consistent with a model in which tissues
accumulate oncogenically activated cells with age and these are held in check by wildtype p53. We also deleted p53 before,
concurrent with, and after treatment of mice with ionizing radiation (IR). The absence or presence of p53 during IR
treatment had no effect on radiation-induced lymphoma latency, confirming that the immediate p53 damage response was
irrelevant for cancer prevention. Even the presence of wildtype p53 for up to four weeks post-IR provided no protection
against early lymphoma incidence, indicating that long term maintenance of functional p53 is critical for preventing the
emergence of a cancer. These experiments indicate that sustained p53 anti-oncogenic function acts as a final or near final
line of defense preventing progression of oncogenically activated cells to malignant tumors.
Citation: Hinkal G, Parikh N, Donehower LA (2009) Timed Somatic Deletion of p53 in Mice Reveals Age-Associated Differences in Tumor Progression. PLoS
ONE 4(8): e6654. doi:10.1371/journal.pone.0006654
Editor: Christopher Kemp, Fred Hutchinson Cancer Research Center, United States of America
Received June 23, 2009; Accepted July 13, 2009; Published August 14, 2009
Copyright:  2009 Hinkal et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the National Institute for Aging (NIA) and from the Ellison Medical Foundation to L.A.D. G.H. was supported by
an NIA training grant. N.P. was supported by a postdoctoral fellowship from AFAR/Ellison Medical Foundation. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: larryd@bcm.tmc.edu
¤ Current address: Unite ´ d’Oncologie Mole ´culaire, Centre Le ´on Be ´rard, Lyon, France
Introduction
Genetic, epigenetic, or functional inactivation of multiple tumor
suppressor genes is a hallmark of human cancers [1]. Among the
most important of the tumor suppressors is p53. The p53 gene is
mutated or lost in roughly half of all human cancers, and
functional inactivation of p53 signaling pathways occurs in many
cancers where the p53 gene remains structurally intact [2,3]. In
response to mutagenic or oncogenic stress, p53 can induce a
transient or permanent cell cycle arrest or it can induce apoptosis
[2]. These anti-proliferative responses of p53 prevent the
emergence of a nascent cancer cell that has been activated
through aberrant oncogene signaling. Oncogenic stress may
activate p53 through ARF signaling or through DNA damage
signaling pathways. In the traditional colorectal multi-step cancer
progression model of Kinzler and Vogelstein, mutation and loss of
p53 function often occurs in the transition from the adenoma stage
to the malignant carcinoma stage, leading to the categorization of
p53 as a ‘‘progression gatekeeper’’ [1,4]. In human cancers, p53
mutation or inactivation can be an early or late event, though it is
unlikely to be an initiating event in most cancers and usually
occurs during cancer evolution or progression [1,5,6].
Mutational studies on human tumors have been very useful in
defining which tumor suppressor genes are important in particular
human cancer types. However, mechanistic studies of tumor
suppressor function have been facilitated by the development of
genetically engineered mice with tumor suppressor gene alter-
ations. We and others have shown that mouse cancer models with
germline p53 deficiency develop many types of tumors much
earlier in their lifespans compared to their p53 competent
counterparts [7–9]. Numerous new mechanistic insights into p53
tumor suppressor functions have been obtained by exploiting these
mouse models [10,11]. More sophisticated methods of manipu-
lating the mouse genome have led to models that allow spatial and
temporal regulation of gene expression [12,13]. Some of the newer
models allow somatic deletion or activation of p53 in specific
tissues. Other models, discussed below, allow global activation or
suppression of p53. The ability to inducibly turn p53 activity on or
off provides a unique experimental flexibility in which p53 tumor
suppressor function can be studied in short defined windows of
time. An example is a recent paper by the Evan laboratory, which
addressed the mechanisms of p53 tumor suppression function in
an illuminating way. Christophorou et al. developed mice
containing an inducible wildtype p53 allele on a p53 null
background [14]. When wildtype p53 was transiently induced
concurrent with ionizing radiation treatment, lymphoid and
intestinal tissues were observed to undergo massive p53-induced
apoptosis. However, no protection from subsequent radiation-
induced lymphomagenesis was observed when compared to
irradiated, non-induced mice, indicating the DNA damage
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to acute stress. However, if wildtype p53 was transiently induced 8
days post-irradiation, circumventing the acute damage response
and instead allowing mutations to develop, significant protection
from radiation-associated lymphomas was noted as these mice
survived 50% longer. This protection was dependent on ARF, a
protein that activates p53 in response to oncogenic stress [15].
Thus, the p53-mediated arrest response to oncogenic activation
(even if short term) is critical for protection from cancer [14]. This
study has been important in shifting our focus from the immediate
DNA damage response mechanisms of p53 to the ARF-mediated
oncogenic response of p53 when considering its primary cancer
suppressive role.
In this paper, we attempted to address aspects of p53 tumor
suppressor function through a novel approach. Instead of
generating p53 germline mutations, we generated mice that allow
global somatic deletion of one or both copies p53 at any chosen
time. We homozygously deleted p53 at various time points before,
concurrent with, and up to four weeks after ionizing radiation and
monitored for radiation-induced lymphomas. Surprisingly, all
groups of irradiated mice exhibited roughly the same median time
to lymphoma formation after deletion of p53 (and much sooner
than p53 deleted non-irradiated controls). Thus, even retention of
p53 for up to 4 weeks post-damage may confer little or no
protection from early lymphomagenesis. Instead, a sustained p53
anti-oncogenic response is required. We also examined the kinetics
of spontaneous tumorigenesis in mice deleted for both p53 alleles
at different ages and compared these to mice with germline
deletions in both p53 alleles. As expected, we found that somatic
p53 deletion delayed onset of tumors compared to those mice with
germline p53 deletions, consistent with the age when p53 was
deleted. However, when median tumor latencies were adjusted for
time post-deletion, mice deleted for p53 at 3 months of age showed
a delay in tumorigenesis relative to mice deleted for p53 at 6 and
12 months of age. We conclude that oncogenically activated cells
accumulate rapidly with age in a p53-independent fashion and
that wildtype p53 likely acts as a critical final or near final line of
defense in suppressing these oncogenically activated clones.
Results
Somatic deletion of p53 in mouse tissues
To examine the effects of global p53 gene deletion at specific
ages in mouse tissues, we employed the strategy outlined in Fig. 1A.
We crossed two genetically engineered mice: ‘‘floxed’’ p53 mice
and Rosa26-CreERT2 knock-in mice (Fig. 1A). Floxed p53 mice
carry an intact wildtype p53 allele containing two loxP
recombination sites (p53
F/F) in introns 1 and 10 of p53 [16].
CreERT2 mice contain a knock-in, modified Cre recombinase
ubiquitously expressed from the Rosa26 locus [17]. The modified
Cre recombinase expressed from the CreERT2 allele is fused to a
mutated form of the estrogen receptor that is non-responsive to
estrogen but highly sensitive to the estrogen receptor antagonist 4-
hydroxytamoxifen (a downstream metabolite of tamoxifen)
rendering it inactive until the addition of ligand [17]. Thus,
intraperitoneal injection of the progeny CreERT2-p53
+/F or
CreERT2-p53
F/F mice with tamoxifen results in activation of the
Cre recombinase and deletion of one (p53
+/F) or both (p53
F/F) p53
alleles spanning exons 2 through 10 in multiple tissues.
The use of tamoxifen as an inducer raised the issue of whether it
could have p53-independent effects on tumorigenesis, since some
studies had shown tamoxifen-induced pathology and DNA adduct
formation in rodent livers [18]. To ascertain whether tamoxifen
injection itself was mutagenic or carcinogenic in mice, we injected
3 month old Stratagene Big Blue transgenic mice with our
standard tamoxifen injection regimen (five consecutive daily
intraperitoneal injections of 1 mg tamoxifen in corn oil). The
Big Blue mouse is a transgenic mouse that contains non-expressed
bacterial selectable markers that can be used to quantify genomic
mutation frequencies in well defined assays [19]. Two or four
weeks after tamoxifen injection, livers were harvested from the
treated mice and genomic DNA was analyzed in the Big Blue
mutation assay. The resulting data indicate that tamoxifen
treatment significantly increases (p2-week=0.0089, p4-week=0.032)
liver mutation frequency by roughly two-fold in mice (Fig. 1B).
However, we found that wildtype mice injected with tamoxifen at
3 months of age exhibit very similar survival curve dynamics
(Tamoxifen treated wildtype mice versus pvehicle=0.269,
pnon-injected=0.572), longevities (maximal lifespan of: tamoxifen
control=1119 days, vehicle control=1162 days) and tumor
susceptibilities as vehicle injected control mice (Fig. 1C). Thus,
tamoxifen injection may lead to a modest increase in liver DNA
mutation frequency but it does not affect overall longevity or
tumor susceptibility.
To detect whether tamoxifen treatment of CreERT2-p53
F/F and
CreERT2-p53
+/F mice was efficient in global excision of p53
throughout all tissue types, we injected several of these mice at three
months of age and harvested a variety of tissues two weeks later.
Examination of genomic DNA from multiple tissues of the
tamoxifen-treated and non-treated mice by PCR analyses showed
no evidence of background p53 allele excision in non-treated mice,
but detectable excision in all tissues of treated mice (Fig. 1D). To
obtain a more quantitative estimate of relative allele excision in
individual tissues of the CreERT2-p53
+/F and CreERT2-p53
F/F
treated mice, Southern blot analysis was performed (Fig. 1E). The
Southern blots showed essentially complete excision of the p53
alleles in spleen and liver and moderate levels of excision of kidney
and lung, and low levels of excision in brain, heart, and eye; similar
to what had been reported previously in the Rosa26-CreERT2 line
[20]. We examined the kinetics of tamoxifen-mediated p53 deletion
in the livers and spleens of CreERT2-p53
+/F and CreERT2-p53
F/F
mice and found significant deletion after just one day of injections
(data not shown). Tamoxifen treatment of 3 and 12-month old
CreERT2-p53
F/F mice resulted in similar efficiencies of allele
excision in each tissue examined, indicating that age does not affect
allele excision frequency (data not shown).
Effects of p53 allele deletion on radiation-induced
lymphomagenesis
To examine the effects of a carcinogen on p53 tumor suppressor
function, we assessed the effects of somatic p53 allele loss on
radiation-induced lymphomagenesis. First, to show that p53 allele
excision affects the p53-mediated apoptotic response to DNA
damage, we performed TUNEL assays on tissue sections of
irradiated spleens (5 hours after 5 Gy IR) from tamoxifen or
vehicle-treated CreERT2-p53
F/F mice. Tamoxifen-injected mice
showed little evidence of apoptotic cells, consistent with the
deletion of p53 in these tissues (Fig. 2A). In contrast, spleen
sections from vehicle-injected and irradiated CreERT2-p53
F/F
mice exhibited high levels of apoptosis, indicating that the p53-
mediated response was intact in these mice. Next, we examined
p53 and p21 (CDKN1A) protein levels in the irradiated and mock-
irradiated spleen tissues of tamoxifen treated and untreated
CreERT2-p53
F/F mice 5 hours post-IR (Fig. 2B). p21 is a target
gene of activated p53 that is transcriptionally induced following
DNA damage. We found that p53 protein was expressed at
moderate to high levels in all tissues where p53 alleles were intact
and at reduced levels where the p53 alleles were excised. As
p53 and Cancer Progression
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F/F and CreERT2
+/F mice display efficient p53 allele excision in many tissues after tamoxifen treatment. (A)
Experimental design to generate mice that can inducibly and somatically delete p53 in many tissues. Floxed p53 alleles are represented by triangle
flanked bars. Cre-excised p53 alleles are indicated by solo triangles. (B) Tamoxifen treatment of wildtype mice moderately elevates liver DNA mutation
frequency. Three month C57BL/6 Big Blue Mice designed to measure mutation frequencies were treated with tamoxifen (five 1 mg daily injections)
and sacrificed at 2 or 4 weeks post-injection and liver DNA subjected to the mutation frequency assay as described in the methods. Mutation
frequencies are shown with or without tamoxifen injection (n=3 for each time point, 6standard error of the mean). (C) Tamoxifen injection of mice
has little or no effect on survival compared to vehicle-injected wildtype mice. Tamoxifen injection of CreERT2 negative p53
F/F and p53
+/F mice (red
curve, n=23) showed similar Kaplan-Meier survival curves as wildtype uninjected mice (black curve, n=55) and vehicle injected CreERT2-p53
+/F mice
(blue curve, n=50). (D) PCR assays show that vehicle-injected CreERT2-p53
+/F tissues exhibit no p53 allele excision, while all tamoxifen-injected
CreERT2-p53
+/F tissues show evidence of p53 allele excision. Upper panels show genotyping PCR where the upper band (F) is the larger non-excised
floxed allele of p53 and the lower band (+) is the non-floxed wild type p53 allele from various CreERT2-p53
+/F tissues. The lower panels show PCR
fragments specific for the excised p53 allele (D). The left set of panels contain results from vehicle (corn oil) treated tissues while the right set of
panels contain PCR results from tamoxifen treated tissues. Note that in the absence of tamoxifen there is no background p53 allele excision and that
in the presence of tamoxifen all tissues show evidence of p53 allele excision. (E) Tamoxifen treatment of CreERT2-p53
+/F and CreERT2-p53
F/F mice
results in efficient p53 allele excision (D) in some, but not all tissues. Southern blot analysis of genomic DNA from various CreERT2-p53
+/F and
CreERT2-p53
F/F tissues was performed as described in the methods. Note that spleen and liver show efficient excision, lung and kidney show partial
excision, while eye and brain show little evidence of excision.
doi:10.1371/journal.pone.0006654.g001
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F/F mice before, during, and after IR demonstrates the role of p53 in suppressing
carcinogen-induced tumorigenesis. (A) Deletion of p53 prior to irradiation prevents robust apoptotic response in CreERT2-p53
F/F mice. Three
month old CreERT2-p53
F/F mice were injected with tamoxifen or vehicle (corn oil) two weeks prior to treatment with 5 Gray ionizing radiation. Five
hours after IR treatment, spleens were harvested and tissue sections subjected to TUNEL assays for apoptotic cells. Note strong apoptotic response in
vehicle treated mice and greatly reduced apoptotic response in tamoxifen-treated mice. Panel to the right shows percentage of TUNEL positive cells
in spleens from untreated mice (No Tx), corn oil injected and non-irradiated mice (vehicle, No IR), corn oil injected and irradiated mice (vehicle, IR),
and tamoxifen injected and irradiated mice (TAM, IR). (B) The p53 damage response is abrogated in tamoxifen injected CreERT2-p53
F/F mice
subjected to IR. Spleens were harvested from non-irradiated (-IR) and irradiated (+IR), non-injected (-INJ) and injected (+INJ 0 or 2 weeks post-
injection) CreERT2-p53
F/F (+Cre) and p53
F/F (-Cre) mice and Western blots performed on tissue lysates using p53, p21, and actin antibodies. Note that
robust p53 and p21 expression indicative of a robust p53 response occurs only in irradiated but non-Cre expressing or non-injected mice. (C) Six
week old CreERT2-p53
F/F mice were subjected to 2.5 Gy ionizing radiation and were injected with tamoxifen either 2 weeks prior (n=10),
simultaneous with (n=14), 2 weeks after (n=11), or 4 weeks after (n=13) IR exposure. Non-irradiated tamoxifen treated mice CreERT2-p53
F/F are
included as controls (n=62). (D) Kaplan-Meier tumor-free survival curves of IR-treated CreERT2-p53
F/F mice show similar lymphoma latency of
lymphomas post injection while non-IR treated tamoxifen-injected mice showed more delayed tumorigenesis. (E) Natural logarithm of mortality rates
fitted using the T4253H smoothing algorithm comparing Gompertz variables from CreERT2-p53
F/F mice injected with tamoxifen at 2 weeks prior and
4 weeks after IR treatment and non-IR treated tamoxifen-treated CreERT2-p53
F/F mice (x-axis in days). Note that the IR-treated mice exhibit high
mortality whether or not p53 is present at the time of radiation.
doi:10.1371/journal.pone.0006654.g002
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with IR and where p53 was not excised. Radiation and tamoxifen
treated CreERT2-p53
F/F mice showed little or no increase in p21
levels, as expected (Fig. 2B).
Experiments by the Evan laboratory performed with mice
containing an inducible wildtype p53 allele showed that after a
carcinogenic insult, p53 could delay cancer if activated several
days after the insult rather than during the insult. This suggested
that the immediate p53-mediated damage response was less
important than the subsequent anti-oncogenic response in
preventing the emergence of tumors [14]. Here, we used the
CreERT2-p53
F/F mice in a reverse manner. Rather than inducing
p53, we deleted both p53 alleles at various time points before,
during, or after 2.5 Grays of ionizing radiation (IR) treatment.
This IR dose is sufficient to induce rapid lymphoma formation in
mice without p53, but insufficient for early lymphomas in wildtype
mice [21]. We injected the CreERT2-p53
F/F mice with tamoxifen
2 weeks prior (-2), during (0), 2 weeks after (+2), and 4 weeks after
(+4) whole body irradiation, ten to twelve mice for each cohort.
Tamoxifen injected non-irradiated CreERT2-p53
F/F mice were
used as controls. Surprisingly, when adjusted for time post-
tamoxifen injection, all four tamoxifen-treated CreERT2-p53
F/F
groups exhibited roughly the same median time to lymphoma
formation and survival curves (p22:0=0.140, p22:+2=0.211,
p22:+4=0.696), considerably earlier than the control mice in
which wildtype p53 was deleted, but without IR treatment
(Fig. 2C,D). The steepness of the post-irradiation survival curves in
Fig. 2D indicated very high mortality rates in tamoxifen treated
and irradiated CreERT2-p53
F/F mice compared to the tamoxifen-
treated, non-irradiated CreERT2-p53
F/F mice. Such high mor-
tality rates were confirmed in Gompertz variable analyses shown
in Fig. 2E, where only modest mortality rate differences were
observed between CreERT2-p53
F/F mice deleted for p53 2 weeks
prior to or 4 weeks after IR treatment (p=0.023). Both of these
rates were dramatically higher than those for tamoxifen treated
but non-irradiated CreERT2-p53
F/F mice (p=0.0016 and
p,0.0001) (Fig. 2E). Thus, even if wildtype p53 is retained for
up to four weeks after radiation, the time to lymphomagenesis is
essentially the same as if p53 was absent during radiation. These
results confirm the earlier data from Christophorou et al. [14] that
an intact and immediate p53 DNA damage response is irrelevant
to subsequent lymphoma susceptibility. However, our data
indicate retention of p53 for even up to 4 weeks post-IR treatment
may confer little or no protection from early lymphomagenesis.
Thus, it seems that a sustained p53 anti-oncogenic response for
months after the initial damage is required for full protection
against early lymphomas.
Spontaneous tumorigenesis in mice with homozygous
p53 allele deletion at 3, 6, and 12 months of age
To determine the effects of losing both p53 alleles at various
ages, we tamoxifen treated CreERT2-p53
F/F mice at 3, 6, and 12
months of age. These mice and control tamoxifen-treated p53
F/F
mice without the CreERT2 allele were then monitored over their
lifespan and examined for kinetics of tumor incidence. Tumor-free
survival curves of CreERT2-p53
F/F mice injected with tamoxifen
at 3, 6, and 12 months were compared with germline p53
2/2 mice
(n=62, 13, 18, and 72 respectively). As expected, tumors arise
later in tamoxifen-treated CreERT2-p53
F/F mice compared to
p53
2/2 mice (Fig. 3A). The 3 month tamoxifen-injected
CreERT2-p53
F/F mice showed a median tumor incidence about
140 days later than the p53
2/2 mice and the two survival curves
paralleled each other very closely. Surprisingly, the survival curve
of the 6 month tamoxifen treated CreERT2-p53
F/F mice
overlapped the 3 month cohort (p=0.598), and developed tumors
at nearly the same mean age as the 3 month old floxed p53 mice
(305 days for the 3 month cohort, 323 days for the 6 month group).
The 12 month old tamoxifen-treated CreERT2-p53
F/F mice
developed tumors with a median incidence of 529 days. When we
adjusted tumor-free survival (Fig. 3B) to the time of tamoxifen
injection, it was clear that later excision of p53 (6 and 12 months)
resulted in a reduced median tumor latency relative to excision of
p53 at 3 months (p3:6=0.005, p3:12=0.014, p6:12=0.389).
Moreover, the tumor-free survival curves increased in ‘‘steepness’’
in the later tamoxifen treated CreERT2-p53
F/F mice, again
suggesting an increase in mortality rates in the older treated mice.
Comparison between the 3 month and 12 month treated
CreERT2-p53
F/F Gompertz variables confirmed increasing mor-
tality rates with later injection (p=0.0007, Fig. 3C). Thus, tumors
in the later injected CreERT2-p53
F/F cohorts exhibit a reduction
in median and maximum tumor-free post-injection survival,
suggesting that these mice have an increased accumulation of
pre-neoplastic or neoplastic clones that require loss of p53 to allow
full tumor progression.
When we performed necropsies and histopathology on the
tumors of the various tamoxifen treated CreERT2-p53
F/F mice,
we found that 3 and 6 month treated mice developed primarily
lymphomas and secondarily soft tissue sarcomas, at ratios of
roughly 2-3:1, similar to that of p53
2/2 mice (Fig. 3D). In
contrast, lymphomas in the 12 month treated CreERT2-p53
F/F
mice comprised only 43% of total tumors, and there were more
soft tissue sarcomas and carcinomas (36 and 14% respectively).
This is more consistent with tumor observations in p53
+/2 mice,
where retention of one wildtype p53 allele promotes later tumors
which are more mixed in type [22].
Discussion
In this paper, our goal was to better understand p53 tumor
suppressor functions by employing a novel experimental approach.
Rather than examining the effects of p53 germline deletion, we
chose to somatically delete p53 in multiple mouse tissues at varying
ages and at varying times before, during, and after a carcinogenic
insult. This approach more accurately mimics the late somatic p53
loss that often occurs in human sporadic tumors (though massive
simultaneous deletion of p53 is admittedly artificial). The bi-allelic
progeny of the CreERT2 Rosa26 knock-in and floxed p53 knock-
in mice allowed a very precise temporal regulation of p53 deletion
in most tissues of the mouse. We found that efficient deletion
occurred within 24 hours of the first tamoxifen injection and that
the age of injection had little effect on deletion efficiencies. While
the p53 gene in tissues such as brain, heart, and eyes were
inefficiently excised, the tissues most susceptible to tumors in
p53
2/2 mice (lymphoid and mesenchymal tissues) were generally
quite susceptible to p53 allele excision. The tumor types observed
in the somatically deleted p53 mice were very similar to those
observed in p53
2/2 mice. The results presented here suggest that
the incomplete p53 allele deletion in some tissues has only
marginal, if any, effects on overall tumor incidence in this model.
The age-specific somatic p53 deletion experiments were
designed to test whether the aging process affects p53 tumor
suppressor functions. When p53 was homozygously deleted at 3, 6,
and 12 months of age, median tumor latencies after p53 deletion
were 171, 123, and 141 days, respectively, compared to germline
deleted p53
2/2 mice with a 128 day median tumor latency. The 6
and 12 month post deletion tumor incidence curves were
significantly different from those of the mice deleted for p53 at 3
months (p=0.005 and 0.014, respectively). In addition to median
p53 and Cancer Progression
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mortality rates also accelerated with age (Fig. 3C). By these
criteria, rates of tumor progression after p53 deletion appear to
increase with age. As shown in the model presented in Fig. 4, we
hypothesize that these effects are the result of age-associated
accumulation and progression of oncogenically activated cell
clones in the mice. At three months of age, few such clones have
accumulated or progressed to a stage where they can form an
immediate cancer once p53 is deleted. Therefore, tumor
development is delayed and mortality rates are low after p53
excision. However, by 12 months, increased numbers of
oncogenically activated clones have progressed and await only
Figure 3. Tumor-free survival curves of CreERT2-p53
F/F mice injected with tamoxifen at 3, 6, and 12 months of age. (A) Kaplan-Meier
survival curves are shown for germline p53
2/2 mice in black (n=72), CreERT2-p53
F/F mice injected with tamoxifen at 3 months in blue (n=62), at 6
months in green (n=13), and at 12 months in red (n=18). (B) Tumor-free survival curves adjusted for time after tamoxifen injection. Line colors
represent the same groups as in A. Note that the CreERT2-p53
F/F mice injected with tamoxifen at 6 and 12 months of age exhibit a similar median
survival as p53
2/2 mice and a reduced median survival compared to their 3 month injected counterparts. (C) Natural logarithm of mortality rates
fitted using the T4253H smoothing algorithm comparing Gompertz variables from CreERT2-p53
F/F mice injected with tamoxifen at 3, 6 and 12
months (x-axis in days) show a significantly increased mortality rate in the 12 month injected mice (p=0.0007). (D) Tumor types observed in CreERT2-
p53
F/F mice treated with tamoxifen at 3 and 6 months are similar to those observed in germline p53
2/2 mice. In 12 month injected CreERT2-p53
F/F
mice, carcinomas show a modest increase and lymphomas a modest decrease.
doi:10.1371/journal.pone.0006654.g003
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on the rapidity of post-deletion tumor latency in the older mice, it
is likely that for some of these precancerous clones, oncogenic
activation of wildtype p53 is the final or near-final barrier
preventing conversion to a malignant tumor. When p53 is deleted,
such clones transition to malignancy. Prior to p53 deletion
oncogenic clones clearly accumulate and evolve in the presence of
active wildtype p53, suggesting that the presence of p53 may have
little or no effect on early neoplastic evolution, but its loss can
certainly accelerate progression to malignancy.
One interesting result in these analyses was that the 3 month
p53 deleted mice had a significant delay in median tumor
incidence relative to germline p53
2/2 mice (p=1.24610
27),
whereas the 6 and 12 month homozygous deletion incidence
curves were not significantly different from germline p53
2/2 mice
(p=0.987 and 0.247, respectively). As one potential explanation
for the tumor latency differences between the p532/2 and 3
month p53 deleted mice, we hypothesize that p53 has a significant
protective effect on genomic integrity during embryogenesis and
early postnatal development, when cell division rates are high and
prone to potential chromosomal abnormalities. p53 has known
roles in G2/M and mitotic spindle checkpoints and centrosome
integrity and its absence would be expected to increase frequencies
of chromosomal missegregation [23,24]. Indeed, 4–6 week old p53
null mice have dramatically higher fractions of aneuploid cells in
bone marrow, lymphoid and other tissues compared to normal
mice [25,26]. Thus, early in life the presence of p53 may protect
against genomic instability that might facilitate formation of
oncogenic clones, whereas later in life it protects against
progression of oncogenic clones, as hypothesized in some models
for p53 tumor suppressor function [27–29].
These experiments also suggest that wildtype p53 cannot
eliminate all oncogenic clones through apoptosis or keep them
permanently arrested through senescence. Instead, activated
wildtype p53 merely holds some of these oncogenic clones in
stasis, suppressing their further malignant evolution only as long as
p53 remains functional. Changes in p53 function may also explain
in part why tumor incidence in wildtype mice rises dramatically
with age. Levine and colleagues have recently demonstrated that
p53 DNA damage responses, transcriptional activities and
apoptotic functions decline significantly in older mice [30]. As
shown in the model in Fig. 4, reduced p53 activity in older p53
wildtype mice could enhance progression of oncogenically
activated clones to malignancy, but this progression would not
be nearly as rapid as in the somatically deleted p53
F/F mice, where
p53 loss is immediate and complete. Moreover, the recently
described cancer resistant transgenic and knock-in mice that
express additional copies or more active versions of p53 could have
more efficient suppression of oncogenically activated cell clones
late into old age [31–34].
Agents that induce acute DNA damage are often carcinogenic.
The capacity for p53 to respond to both DNA damage and
aberrant oncogenic signals suggested that both activities might be
important in its tumor suppressor function following a carcino-
genic insult such as ionizing radiation treatment. However,
Christophorou et al. [14] showed in recent experiments on mice
expressing an inducible wildtype p53 allele that the immediate p53
DNA damage response was irrelevant to prevention of radiation-
induced lymphomas. Instead, the ARF-dependent p53 response to
oncogenic activation was critical for delaying lymphomagenesis.
Here, rather than activating p53 following treatment of mice with
ionizing radiation, we deleted p53 at various time points before,
concurrent with, and after irradiation. In many ways, our results
confirm those of the Evan laboratory [14]. Whether or not
wildtype p53 was present at the time of radiation treatment had no
effect on subsequent lymphoma incidence. Mice in which p53 was
deleted before, during, or after IR treatment displayed the same
lymphoma latency. Surprisingly, however, we found that retention
of wildtype p53 for as long as four weeks post IR treatment
conferred no additional protection from lymphoma than mice that
were deleted for p53 two weeks prior to radiation. Mice in which
p53 was deleted four weeks after IR treatment showed the same
median lymphoma latency and mortality rate as did mice in which
p53 was deleted two weeks before irradiation (p=0.696), relative
to when p53 was deleted. This indicates that sustained wildtype
p53 function is critical for suppressing tumorigenesis and that p53
may only keep some oncogenically activated cells in check rather
than permanently disable or destroy them. This absence of
Figure 4. p53 acts as a gatekeeper by preventing progression
of oncogenically activated cells to full malignancy. From left to
right 20 month old wildtype p53 mice, p53
F/F mice with intact p53 until
3 and 12 months of age, and 6 week old irradiated p53
F/F mice are
shown. All of these mice accumulate oncogenically activated clones
with age, though irradiation greatly enhances the numbers of such
clones. Oncogenically activated clones are represented by yellow (early
stage oncogenic clones that are not yet capable of tumor formation)
and orange (later stage oncogenic clones capable of tumor formation
upon loss of p53) circles. These clones are held in check by wildtype
p53, which prevents their progression to full malignancy. However,
after the age of 20 months in wildtype mice, p53 functional activities
decline, which could lead to malignant progression of one or more
oncogenic clones (cancers indicated by red circle). When p53 is deleted
by tamoxifen injection at 3, 6, or 12 months or following IR treatment in
CreERT2-p53
F/F mice, some oncogenic clones will progress to form a
malignant cancer. For the p53
F/F mice, the median and maximal tumor
latencies following p53 deletion decrease with age or with carcinogenic
insult. The relative tumor latencies are indicated by the length of the
red vertical arrows. For the wildtype mice, since p53 activity is merely
reduced, malignant progression is more delayed. The small graphs
below each of the tumor bearing mice shows the shape of the survival
curves for each cohort, indicating that tumor latencies and mortality
rates depend on p53 functional status, age, or the presence of
carcinogenic insult. Thus, p53 acts as a final or near-final gatekeeper
keeping these oncogenic clones from progressing to full malignancy.
doi:10.1371/journal.pone.0006654.g004
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observed differed from that observed by the Evan group, who
showed that even a short six day activation of wildtype p53 eight
days post-IR resulted in a significant delay in tumorigenesis. The
reasons for the discrepancies are unclear, though they may be due
to different features of the two models or that the Evan p53-ER
fusion protein was a more robust tumor suppressor being activated
in a cellular environment previously missing p53 entirely.
These studies support a model in which p53 acts as a
‘‘progression gatekeeper’’ preventing oncogenically activated cell
clones from becoming fully malignant. Such cell clones progress
and increase in numbers with age and p53 may act as a final or
near final line of defense against cancer. It is only with old age that
p53 anti-cancer function may decline and cancers may finally
emerge (Fig. 4). We have also confirmed that the acute DNA
damage response of p53 is likely to be unimportant and that a long
term continuous p53 response to oncogenically activated cells is
likely to be critical for cancer suppression. While p53 may prevent
cancer progression by inducing apoptosis or senescence in some
oncogenically activated cells, for other such clones it merely
prevents further malignant evolution. The somatic p53 deletion
model presented here has been a source of useful insights into p53
tumor suppressor function and it may provide additional insights
through further experimental manipulations.
Materials and Methods
Mice
Ethics Statement. All animals were handled in strict
accordance with good animal practice as defined by the
Institutional Animal Care and Use Committee for Baylor
College of Medicine and Affiliates (Animal Protocol AN336) and
by the Association for the Assessment and Accreditation of
Laboratory Animal Care (AAALAC), Guide for the Care and Use
of laboratory Animals (NRC1996).
FVB.129 doubly floxed (p53
F/F) mice were obtained from the
National Cancer Institute Mouse Models of Human Cancers
Consortium and were originally generated by Anton Berns as
previously described [16]. These mice were backcrossed into a
C57BL/6 background. C57BL/6.SLJ CreERT2 homozygous
mice were obtained from Artemis Pharmaceuticals GmbH [17]
and backcrossed into a C57BL/6 background. C57BL/6 Big Blue
mice were obtained from Stratagene (Austin, TX). All mice were
bred and maintained in a specific pathogen-free animal facility at
Baylor College of Medicine. CreERT2-p53
F/F mice were
generated by successive crossing of CreERT2 and p53
F/F mice
and genotyping by PCR as described below. All research with
mice has been conducted in compliance with the Baylor Animal
Protocol Committee (Baylor College of Medicine Animal Protocol
AN336) and AAALAC recommendations as published in the The
Guide for the Care and Use of Laboratory Animals (NRC1996).
Allele genotyping. High molecular weight genomic DNA
was prepared from 5 mm tail tips or 50 mg tissue and prepared as
previously described [35]. All PCR primers were synthesized by
Integrated DNA Technologies (Coralville, IA). The presence of
the CreERT2 gene was verified using the primers Cre-F: 59-AAG
AAC CTG ATG GAC ATG TTC AGG G-39 and Cre-R: 59-
CCA GAC CAG GCC AGG TAT CTC T-39, which produce a
790 bp product following standard PCR. Genotyping for the
floxed p53 allele was performed using primers in p53 intron 10,
Int10FOR: 59-AAG GGG TAT GAG GGA CAA GG-39 and
Int10REV: 59-GAA GAC AGA AAA GGG GAG GG-39. Using
these primers, wildtype p53 alleles produce a 431 bp fragment,
while the floxed p53 allele produces a 584 bp fragment following
PCR. Successful excision of exons 2–10 by Cre recombinase was
verified with PCR using primers Int10REV and Int1FOR (59-
CAC AAA AAC AGG TTA AAC CCA G-39).
p53 allele deletion. Tamoxifen (Sigma Aldrich, St. Louis,
MO) was prepared at a concentration of 10 mg/ml in 5%
ethanol/95% corn oil (after first suspending in 100% ethanol). To
activate the CreERT2 recombinase, CreERT2 allele-containing
mice were injected intraperitoneally with 100 ml tamoxifen
solution (1 mg tamoxifen per injection) daily for five consecutive
days at the ages of 3, 6, and 12 months for aging cohort
experiments. To quantitate the relative efficiency of p53 allele
deletion in specific tissues of CreERT2-p53
+/F and CreERT2-
p53
F/F mice, genomic DNA was purified as described above from
50 mg of each tissue and 5–10 mg of DNA was digested with 10
units of Bgl II (New England BioLabs, Ipswich, MA) for 16 hours
at 37uC. The restricted DNA was subjected to electrophoresis in a
0.8% agarose gel and Southern blotted using standard methods.
The blot was hybridized to a
32P-labeled mouse p53 exon 11 DNA
probe prepared from wildtype genomic DNA with PCR fragments
generated from primers Ex11FOR (5-CTA CCT GAA GAC
CAA GAA GG-39) and Ex11REV (59-TGG AGG ATA TGG
ACC CTA TG-39). After hybridization and washing of the
Southern blot followed by autoradiography, the relative intensity
of hybridization in the intact p53 allele (20 kb), the excised p53
allele (10 kb) and a p53 pseudogene (2 kb) was quantitated on a
GE Molecular Dynamics phosphorimager. Relative efficiencies of
excision in tamoxifen-treated CreERT2-p53
+/F and CreERT2-
p53
F/F tissues could be determined after normalizing band
intensities to the pseudogene band and to wildtype p53 bands in
non-treated control CreERT2-p53
+/F and CreERT2-p53
F/F
tissues.
Western blotting. Freshly excised tissue samples were
harvested, snap frozen in liquid nitrogen, and stored at -80
uC
until use. Tissues lysates were prepared by homogenization of
approximately 50 mg tissue as previously described [36]. For
Western blots, 75 mg tissue lysates were loaded per SDS-
polyacrylamide gel and analyzed as previously described [36].
Antibodies to p53 (R-19) and p21 (F-5) were from Santa Cruz
Biotechnology (Santa Cruz, CA). Actin antibodies were obtained
from NeoMarkers (Fremont, CA).
Big Blue mutation frequency assay. To determine the
effects of tamoxifen on mutation frequencies, wildtype C57BL/6
Big Blue mice from Stratagene were injected daily for five
consecutive days with 1 mg of tamoxifen in 100 ml of corn oil.
Mice were sacrificed at two or four weeks after the first injection
and high molecular weight genomic DNA was prepared from the
livers of treated and non-treated animals. The determination of
mutation frequencies in the liver DNA of tamoxifen treated and
non-treated Big Blue mice was performed according to the
manufacturer’s guidelines and the methods have previously been
described in Hinkal et al. [36].
Lifespan analyses. All treated and non-treated mice were
monitored on a daily basis for morbidity or death as previously
described. Severely morbid mice were euthanized. Mice that died
overnight and euthanized mice were subjected to gross necropsy
and organs and tumor lesions were fixed in 10% neutral buffered
formalin, paraffin embedded and hematoxylin and eosin slides
prepared in the Veterinary Pathology Core at Baylor College of
Medicine. Slides were examined and tumors were classified
histopathologically as to type. Survival curve comparisons for
each cohort of mice were performed using statistical software for
Kaplan-Meier Survival Analysis with Tarone-Ware statistics
(SPSS Inc, Chicago). Mortality rates were calculated and
compared as described by de Magalhaes et al. [37]. Briefly,
p53 and Cancer Progression
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to calculate the hazard of death with age. These data were
compared to other cohort mortality rates on a natural log scale
and slopes compared by t-test.
Irradiation-induced lymphomagenesis. To assess the
effects of p53 allele status on radiation-induced lymphomagenesis,
CreERT2-p53
F/F mice were treated with tamoxifen for 5
consecutive days as described earlier. 5–7 weeks old mice were
subjected to 2.5 Grays whole body ionizing c-radiation using a
Cesium-137 source (MDS Nordion GammaCell 40 Exactor) 2
weeks prior to, concurrent with, 2 weeks after, or 4 weeks after
tamoxifen treatment. Mice were then regularly monitored for
morbidity or death whence necropsies and tumor-free survival
curves were performed as described above.
TUNEL assay. For assessing the effects of p53 allele status on
IR-induced apoptosis, 3 month old CreERT2-p53
F/F mice were
injected with tamoxifen (1 mg/day) or vehicle (corn oil) for 5
consecutive days. Three weeks after the first injection, mice were
either left untreated or were exposed to 5 Grays whole body c-
irradiation. At 5 h post-irradiation, spleens were harvested and
fixed in 10% buffered formalin. Tissues were processed, paraffin
embedded, and sections (5 mm) were cut at the Baylor College of
Medicine Histology Core. Immunostaining for apoptosis was
performed using the In Situ Cell Death Detection Kit, Fluorescein
(Roche Applied Science, Indianapolis, IN) as per manufacturer’s
instructions. Sections were counterstained with DAPI (1 mg/ml)
and imaged at 406magnification under a fluorescence microscope
(Zeiss Axioplan2, Carl Zeiss MicroImaging GmbH) using
appropriate filters. Fluorescein labeled cells were scored as
positive for TUNEL staining. For each tissue section, at least 3
fields were counted and the average percentage of TUNEL
positive cells from 3 spleens for every condition was plotted.
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